Galderma has earned another FDA-approval for its popular filler brand Restylane.
Monday morning, Galderma announced that its hyaluronic acid dermal filler, Restylane Lyft, has been approved by the Food and Drug Administration for application to the midface and cheeks via a cannula needle.
You May Also Like: The FDA Is Ordering These Beauty Products to Remove Lead From Their Formulas
This means that the small blunt cannula needle can now be used for treatments like cheek augmentation and age-related midface contouring.
The cannula needle’s tube is thin and flexible with openings on the side to deliver filters more effectively. New York dermatologist and clinical trial investigator, Anne Chapas, MD says she prefers using a cannula over a needle when injecting Restylane Lyft into certain areas of the face. “In my experience, the use of a cannula may be associated with less potential damage to blood vessels, helping to minimize patient bruising and decrease swelling, and allowing for minimized downtime.”
Although it’s the only hyaluronic acid (HA) filler to be used via cannula in this area, it’s the second FDA-approved cannula indication, after Restylane Silk for lip augmentation.
“We have increased our investment in research and development this year in order to help grow the aesthetic market,” says general manager and vice president of the U.S. Aesthetic Business at Galderma, Alisa Lask, says in this morning’s press release. “Our goal is to continue to offer new solutions and delivery systems to our customers to help drive new patients in to aesthetic offices.”